NCT03405168View on ClinicalTrials.gov

Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

July 30, 2018

Study Completion Date

July 30, 2018

Conditions
Advanced Breast CancerAntibioticStable Disease With a Trend of Progression
Interventions
DRUG

Moxifloxacin Hydrochloride 400mg Tablet

Moxifloxacin is oral administration, 400 mg once a day, D1 to D7, 28 days as one cycle.

Trial Locations (1)

510000

Zhongyu Yuan, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT03405168 - Routine Therapy Plus Moxifloxacin in Advanced Breast Cancer | Biotech Hunter | Biotech Hunter